We aimed to determine the role of red blood cell (RBC) total folate in predicting the pemetrexed response in advanced nonsquamous nonesmall-cell lung cancer. Patients with low pretreatment RBC total folate concentrations had an inferior response rate to pemetrexed-based chemotherapy. Our study results suggest the potential use of RBC total folate, a widely available and low-cost assay, for predicting the pemetrexed response. Introduction: Pemetrexed inhibits folate-dependent enzymes involved in pyrimidine and purine synthesis. Previous studies of genetic variation in these enzymes as predictors of pemetrexed efficacy have yielded inconsistent results. We investigated whether red blood cell (RBC) total folate, a phenotypic rather than genotypic, marker of cellular folate status was associated with the response to pemetrexed-based chemotherapy in advanced nonsquamous nonesmallcell lung cancer (NSCLC). Materials and Methods: We conducted a prospective cohort study of patients with stage IV nonsquamous NSCLC receiving first-line chemotherapy containing pemetrexed. The pretreatment RBC total folate level was quantified using liquid chromatography mass spectrometry. We then compared the objective response rate (ORR) between patients with RBC total folate concentrations greater than and less than an optimal cutoff value determined from the receiver operating characteristic curve. A logistic regression model was used to adjust for age, sex, and the use of bevacizumab. Results: The ORR was 62% (32 of 52 patients). Receiver operating characteristic analysis was used to establish that a RBC total folate cutoff value of 364.6 nM optimally discriminated between pemetrexed responders and nonresponders. Patients with RBC total folate < 364.5 nM had an ORR of 27% compared with 71% for patients with RBC total folate > 364.5 nM (P ¼ .01). This difference persisted after adjusting for age, sex, and the use of bevacizumab (odds ratio, 0.07; 95% confidence interval, 0.01-0.57; P ¼ .01). Conclusion: A low pretreatment RBC total folate was associated with an inferior response to pemetrexed-based chemotherapy in stage IV nonsquamous NSCLC. Larger, multicenter studies are needed to validate RBC total folate as a predictive marker of pemetrexed response.
Introduction
Nonesmall-cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality, 1 and most patients present with advanced-stage disease. Despite recent advances in NSCLC therapy, cytotoxic chemotherapy with a platinum-based doublet remains the mainstay of first-line treatment. 2 Although no randomized trial has demonstrated superiority for 1 platinum-based doublet compared with another for unselected patients with advanced or metastatic disease, a prespecified analysis of a phase III first-line study demonstrated superior overall survival (OS) with pemetrexed plus cisplatin compared with gemcitabine plus cisplatin in patients with nonsquamous histologic features. 3 Pemetrexed primarily targets thymidylate synthase (TS), a folate-dependent enzyme involved in DNA synthesis, DNA repair, the proliferation of cancer cells, and dihydrofolate reductase and glycinamide ribonucleotide formyltransferase. 4, 5 Although pemetrexed-based chemotherapy is the most commonly used regimen for patients with nonsquamous histologic features, the reported objective response rate (ORR) has been approximately 30%. 3, 6 The identification of predictive biomarkers other than nonsquamous histologic features is needed to improve the selection of patients who will derive the most benefit from pemetrexed-based chemotherapy. Intratumor TS expression might be 1 marker of a poor response to pemetrexed in patients with NSCLC, because patients with TS-positive tumors had an inferior ORR and progression-free survival (PFS) in a recent randomized phase II trial. 7 However, the practical utility of intratumor TS expression is limited by the requirement for adequate tissue and the subjective nature of current immunohistochemical approaches for the assessment of TS expression and to identify an appropriate cutoff value to determine positivity. Genetic variation in cellular folate metabolism, specifically polymorphisms in MTHFR (encoding 5,10-methylenetetrahydrofolate reductase) and TYMS (encoding TS), could also affect the tumor response to pemetrexed, although the results of previous studies have been inconsistent. [8] [9] [10] [11] [12] [13] [14] [15] [16] Because of the limitations of existing biomarkers, novel predictors of pemetrexed response are needed. We hypothesized that a blood-based phenotypic biomarker of folate status would be both practical and effective as a predictor of pemetrexed response. Accordingly, we investigated whether the pretreatment red blood cell (RBC) total folate concentration is associated with the response to pemetrexed-based chemotherapy in patients with nonsquamous NSCLC.
Materials and Methods

Patients, Study Design, and Treatment
We conducted a single-center, prospective cohort study to determine whether the pretreatment RBC total folate concentration was associated with the response to pemetrexed-based chemotherapy in patients with newly diagnosed stage IV histologically confirmed nonsquamous NSCLC. The eligibility criteria included the use of pemetrexed-and platinum-containing regimen, measurable disease using the Response Evaluation Criteria In Solid Tumors, version 1.1, and no previous systemic therapy for NSCLC. All patients were enrolled from September 2010 to March 2013 at the University of Pennsylvania and provided written informed consent. The institutional review board of the University of Pennsylvania approved the study.
All patients received carboplatin (area under the curve [AUC] 5-6) with pemetrexed 500 mg/m 2 once every 3 weeks. The use of bevacizumab 15 mg/kg, colony-stimulating factors, and erythropoiesis-stimulating agents was allowed. Dose adjustment and cycle delays were allowed for resolution of toxicities. After 4 to 6 cycles of combination chemotherapy, the decision to continue with pemetrexed maintenance (with or without bevacizumab) was at the discretion of the treating physician. All patients received vitamin supplementation with 1 mg of oral folic acid daily and a 1000-mg intramuscular vitamin B 12 injection given every 9 weeks. A 1-week run-in course of these vitamins was given to mitigate toxicity at, or soon after, the onset of chemotherapy. Baseline 25-mL blood samples and the preparation of samples for measuring RBC total folate concentrations were performed before vitamin supplementation and chemotherapy administration. The treating physicians were unaware of the results of the patients' pretreatment RBC total folate concentrations. The response to chemotherapy was assessed using the Response Evaluation Criteria In Solid Tumors, version 1.1, and computed tomography scans on a schedule determined by the treating physician. All initial radiographic response assessments occurred after either the second or third cycle of chemotherapy. The treatment outcomes were categorized as a partial response, stable disease, or progression. From these serial evaluations, the best outcome was used for the response rate evaluation. The ORR was calculated as the percentage of partial responses among all treated patients.
RBC Total Folate Measurement
The baseline RBC tetrahydrofolate (THF), 5-methyltetrahydrofolate (5-MTHF), and 5,10-methenyltetrahydrofolate (5,10-MTHF) levels were quantified as absolute nanomolar concentrations using a stable isotope dilution liquid chromatography, multiple reaction monitoring, mass spectrometry-based method. 17 This method permits the accurate quantification of folate analytes in RBCs. 17, 18 The RBC total folate concentration was calculated as the sum of these 3 analytes.
Genotype Analysis
In an exploratory analysis, we sought to determine whether the relationship between the RBC total folate concentration and the pemetrexed response might be underpinned by polymorphisms in the MTHFR and/or thymidylate synthase (TYMS ) genes. DNA was extracted from the blood samples and genotyped using a custom microarray based on Illumina BeadChip technology (Illumina, San Diago, CA). 19 We analyzed 3 exonic single nucelotide polymorphisms (SNPs) in the MTHFR gene [rs1801131 (1298A>C), rs1801133 (677C>T), and rs2274976 (1793G>A)], and 2 exonic SNPs in the 3 0 -untranslated region of the TYMS gene (rs2790 and rs699517). Each of these 5 SNPs was evaluated for an association with the RBC total folate concentration.
Statistical Analysis
All statistical analyses were performed using Stata, version 14.1 (StataCorp, College Station, TX). Demographic characteristics were described using frequencies and percentages for categorical variables
Pretreatment RBC Total Folate and Nonsquamous NSCLC and the median and range for quantitative variables. The performance of the pretreatment RBC folate concentration to discriminate between pemetrexed responders and nonresponders was evaluated using receiver operating characteristic curves and calculation of the AUC. The best cutoff level of RBC total folate for predict the response was selected using the Youden index, an objective method that maximizes the sum of sensitivity and specificity. 20 The c 2 test was used to determine the statistical significance (established at P < .05) of the association between the RBC total folate concentration, as determined by the optimal cutoff point, and the primary clinical outcome of ORR. We repeated this analysis using logistic regression to adjust for age (categorized as < 60 years, 60-69 years, and 70 years), sex, and the use of bevacizumab concurrently with pemetrexed-based chemotherapy.
The secondary analyses included evaluation of the association of RBC total folate with PFS and OS. PFS was defined as the interval in months between the start of treatment and death or progression, whichever occurred first (or censored at the date last seen). OS was defined as the interval in months between the start of the treatment and death or censored at the date of last patient contact. We calculated PFS and OS using the Kaplan-Meier method and used Cox proportional hazards models to adjust for age, sex, and bevacizumab administration.
To determine whether the difference in response rate according to the RBC total folate concentration was attributable to absolute concentrations of 1 folate analytes or to the relative concentrations of folate analytes, we used the Wilcoxon rank-sum test to compare the concentrations of each analyte (5-MTHF, THF, and 5,10-MTHF) and the ratio of 5-MTHF to THF concentrations between responders and nonresponders.
For genotype analysis, each of the 5 SNPs (dichomitized as homozygous for the more common allele vs. heterozygous or homozygous for the less common allele) was evaluated for its association with the RBC total folate concentration using the Wilcoxon ranksum test. The association of each SNP with the response to pemetrexed was also assessed using Fisher's exact test. Bonferroni's correction for multiple testing was undertaken, and P < .01 (¼ .05/ 5) was set as the level of significance.
Results
Baseline Characteristics and Treatment
The baseline characteristics of the 52 study participants are listed in Table 1 . The pretreatment RBC total folate concentration ranged from 118.6 to 2553.1 nM (mean, 693.4 nM; median, 560.3 nM). All patients received pemetrexed with carboplatin, and 27 (52%) also received concurrent bevacizumab. The ORR was 62% (32 of 52 patients), with all responses occurring before the fourth cycle of chemotherapy. The best responses for the remaining 20 patients included stable disease in 12 (23%) and progressive disease in 8 (15%). Of the 44 patients who achieved a response or had stable disease after 3 cycles, 17 (39%) subsequently received a total of 4 cycles, 5 (11%) received 5 cycles, and 22 (42%) received 6 cycles. Five patients developed progression between cycles 4 and 6 of combination chemotherapy. Of the 39 patients whose disease had not progressed during combination chemotherapy, 29 (74%) subsequently received pemetrexed maintenance therapy (with or without bevacizumab).
RBC Total Folate Concentration and Response to Pemetrexed
A pretreatment RBC total folate cutoff value of 364.6 nM optimally discriminated between pemetrexed responders and nonresponders. The receiver operating characteristic curve that included all possible cutpoints resulted in an AUC of 0.61 (95% confidence interval [CI], 0.45-0.73). A total of 11 patients (21%) had pretreatment RBC total folate levels < 364.6 nM and 41 patients (79%) had concentrations > 364.6 nM. The ORR was 27% (3 of 11 patients) in the lower RBC total folate group (RBC total folate concentration < 364.6 nM) and 71% (29 of 41 patients) in the higher group (P ¼ .01). After adjusting for age, sex, and bevacizumab administration, a significantly lower likelihood of a response to pemetrexed remained for patients in the lower RBC total folate group (odds ratio, 0.07; 95% CI, 0.01-0.57; P ¼ .01; Table 2 ).
We then assessed for differences in individual folate analyte levels between the patients with a response to pemetrexed-based chemotherapy and those with no response. The median concentration of 5-MTHF was greater in the pemetrexed responders compared with nonresponders, although this did not reach statistical significance (537.8 nM vs. 379.1 nM; P ¼ .06). In contrast, no differences were found in the concentrations of THF (P ¼ .61), 5,10-MTHF (P ¼ .37), or the ratio of 5-MTHF to THF (P ¼ .76) between the responders and nonresponders (Figure 1) .
Of the 31 patients with a high RBC total folate concentration who had a response or stable disease after 4 to 6 cycles of combined chemotherapy, 21 (68%) received pemetrexed maintenance. The 
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Clinical Lung Cancer March 2017 -e145 remaining 10 patients (32%) with high RBC total folate concentrations were either deemed unfit to continue with any maintenance therapy (n ¼ 1) or received bevacizumab maintenance alone (without pemetrexed; n ¼ 9). All 8 patients (100%) with a low RBC total folate concentration with a treatment response or stable disease received pemetrexed maintenance. The median PFS for the cohort was 6.3 months (95% CI, 4.9-8.3 months), and the median OS was 13.5 months (95% CI, 9.7-19.5 months). A greater pretreatment RBC total folate concentration was not associated with an improvement in PFS (adjusted hazard ratio, 1.06; 95% CI, 0.53-2.14; P ¼ .87) or OS (adjusted hazard ratio, 1.00; 95% CI, 0.47-2.14; P ¼ .99) after controlling for age, sex, and the receipt of bevacizumab (Figure 2) .
Analysis of MTHFR and TYMS Variants With Response to Pemetrexed
DNA samples were available for genotyping for 42 of the 52 patients (81%). A single variant (rs1801131; 1298A>C) in MTHFR that specifies a functional glutamate to alanine change at amino acid 429 was significantly associated with the RBC total folate level, with lower RBC total folate levels observed in patients with a homozygous CC or heterozygous AC genotype compared with those with a homozygous AA genotype (P ¼ .005; Figure 3) . However, the differences in these genotypes did not reach statistical significance for an association with the pemetrexed response (P ¼ .18). No other variants considered in the present analysis were associated with either the RBC total folate concentration or the pemetrexed response.
Discussion
Pemetrexed-based chemotherapy is widely used for advanced or metastatic nonsquamous NSCLC; however, the response rate has been only approximately 30% to 34%. 3, 6 Reliable predictive markers are needed to distinguish patients more likely to benefit from first-line pemetrexed-based chemotherapy from those who might be better served by initiating treatment with an alternative agent. In the present prospective single-institution study, we found that the pretreatment RBC total folate concentrations were useful in predicting the probability of a response to pemetrexed-based chemotherapy. To our knowledge, a blood-based predictive biomarker of pemetrexed response based on a phenotypic, rather than genotypic, marker of folate status has not previously been described. Because we measured the individual folate analyte concentrations, we were also able to evaluate whether the effect of the RBC total folate concentration on the response to pemetrexed was attributable to the absolute concentrations of 1 of the analytes or, alternatively, their relative concentrations. We found that the concentration of 5-MTHF, the major circulating form of folate and the most prominent RBC analyte in most individuals, 18 tended to be greater in the pemetrexed responders than in the nonresponders. In contrast, the THF and 5,10-MTHF concentrations and the ratio of 5-MTHF to THF concentrations were similar across both groups. Taken together, these findings suggest that it is the absolute concentration of RBC folate (primarily driven by the 5-MTHF concentration), rather than the relative proportions of the individual folate analytes, that is predictive of the response to pemetrexed.
Although a low RBC total folate concentration was not associated with inferior OS or PFS, the present study was not powered to detect differences in survival. Furthermore, OS and PFS could have been influenced by subsequent therapies after progression with pemetrexed and by variations in the use of maintenance pemetrexed, respectively. For example, among patients with a treatment response or stable disease after 4 to 6 cycles of combination chemotherapy, all those with low RBC total folate levels received maintenance pemetrexed compared with only two thirds of those with high RBC total folate concentrations. Finally, the relationship between the response rate and OS in patients with advanced NSCLC has not been firmly established. 21 Thus, it is possible that the difference in response rate predicted by the RBC total folate concentration might have no effect on survival. Many previous studies have attempted to identify the biomarkers associated with pemetrexed sensitivity. Because the histologydependent differential efficacy of pemetrexed treatment between patients with nonsquamous cell and squamous cell carcinoma correlates with lower TS expression with the former tumor type, 7, [22] [23] [24] Figure it has been hypothesized that lower tumor TS expression might serve as a predictive biomarker of increased pemetrexed sensitivity within the nonsquamous NSCLC patient population. 25 This hypothesis was ultimately supported by a biomarker-stratified, randomized trial of patients with nonsquamous NSCLC that demonstrated increased clinical benefit from pemetrexed in TS-negative patients compared with TS-positive patients. 7 However, the practical utility of intratumor TS expression is limited by the need to acquire adequate tissue samples at biopsy or surgery and a laboratory capable of properly processing such samples and quantifying and interpreting TS expression. The concentration of RBC total folate, the biomarker used in our study, can be easily determined from peripheral blood samples and can be measured by most hospital laboratories using commercial kits. If our findings are ultimately replicated in a larger study and show a survival differential, the RBC total folate concentration could be readily used as a predictive marker of response to pemetrexed.
Other studies aimed at identifying biomarkers to predict the response to pemetrexed have explored genetic variations in enzymes related to cellular folate metabolism, in particular TYMS polymorphisms. However, previous analyses of the relationship between such polymorphisms and outcomes in patients with NSCLC treated with pemetrexed-containing regimens have had conflicting results. Several studies have shown that an increased number of 28-bp variable number tandem repeat sequences in the 5 0 -untranslated region of the TYMS gene (ie, the 3R/3R genotype) and/or a 6-bp insertion/deletion polymorphism in the 3 0 -untranslated region of TYMS might influence the outcomes with pemetrexed. 10, 11, 13, 15 However, others have demonstrated the opposite results or no association at all. [12] [13] [14] Similarly, 2 previous studies concluded that NSCLC patients who were homozygous for a substitution of thymine for cytosine in nucleotide 677 of the MTHFR gene (ie, 677TT genotype) had improved PFS with second-line pemetrexed. 9, 16 However, 2 subsequent studies failed to demonstrate any association between MTHFR genotypes and the outcomes with pemetrexed. 11, 12 Numerous potential reasons exist for why studies of the genetic markers of pemetrexed response have shown inconsistent results. Most importantly, TYMS and MTHFR are only 2 of many enzymes, as well as receptors and transporters, that influence folate metabolism. Thus, it is likely that polymorphisms in multiple genes contribute to differences in the effects of pemetrexed within a population. RBC total folate, the biomarker used in our study, serves as a key phenotypic, rather than genotypic, marker of folate metabolism. As such, the RBC concentration of total folate represents the net, measurable endpoint that results from the variable activities of multiple receptor, transporter, and enzyme polymorphisms.
Our exploratory genetic analysis indicated that the MTHFR 1298A>C polymorphism, a variant resulting in decreased efficiency of the MTHFR enzyme, is significantly associated with lower RBC total folate concentrations. This association makes sense, because decreased efficiency of MTHFR results in lower intracellular concentration of 5-MTHF, the key circulating form of folate and most prominent RBC folate analyte in most individuals. The lack of a statistically significant association between this polymorphism and a response to pemetrexed might reflect the effects of multiple nongenetic and nonfolate-related influences on pemetrexed response, such as TS protein expression. 7 However, it is interesting that the MTHFR 1298A>C polymorphism has been previously associated with lower PFS in patients receiving second-line pemetrexed therapy for advanced NSCLC 9 and reduced OS for patients treated with pemetrexed for advanced gastric adenocarcinoma. 26 It is possible that our small sample size precluded the detection of a PFS or OS difference according to this polymorphism. Thus, larger studies are needed to definitively assess the association of MTHFR 1298A>C and MTHFR 677C>T with the RBC total folate concentration and pemetrexed response. The mechanism through which a low baseline RBC total folate concentration was associated with inferior response to pemetrexed in our study is not known. The MTHFR 1298A>C polymorphism, a variant associated with decreased efficiency of the MTHFR enzyme and with lower RBC total folate in our study, might lead to greater intracellular concentrations of 5,10-methylenetetrahydrofolate, which competes with pemetrexed for interaction with the TS enzyme. 8 It is therefore conceivable that greater concentrations of 5,10-methylenetetrahydrofolate result in increased competition with pemetrexed for inhibition of the TS enzyme, thereby lowering pemetrexed efficacy. However, separate studies are needed to formally test this hypothesis. Our study had several limitations. The sample size was small, because our study was designed to determine the feasibility of using the RBC total folate concentration as a biomarker of pemetrexed response and to derive an optimal RBC folate cutoff value. Thus, our study cohort included a high proportion of women and was younger than the general NSCLC population. In addition, the overall response rate was greater than expected from previous phase III studies of pemetrexed-based chemotherapy. These differences from a typical NSCLC population might limit the generalizability of our findings. Finally, we could not rule out the possibility that a low pretreatment RBC total folate concentration is a biomarker for lower socioeconomic status and general nutritional health, both of which are potential confounders in the relationship between RBC total folate and the response to pemetrexed-based chemotherapy. However, it seems unlikely that socioeconomic status and general nutritional health would lead to differences in the objective radiographic tumor response, in particular, without a difference in PFS or OS.
Conclusion
A low pretreatment RBC total folate concentration was associated with an inferior response to pemetrexed-based chemotherapy in stage IV lung adenocarcinoma. Larger, multicenter studies are needed to validate RBC total folate as a predictive biomarker of pemetrexed in NSCLC.
Clinical Practice Points
Pemetrexed is used extensively in nonsquamous NSCLC without a reliable biomarker of response. A low pretreatment RBC total folate concentration was associated with a lack of response to first-line pemetrexed plus platinum in advanced nonsquamous NSCLC. The results of our study suggest the potential use of RBC total folate measurement, a low-cost and widely available test, for predicting the pemetrexed response.
